Following ASCT for multiple myeloma, it is unclear whether relapse is due solely to the presence of residual myeloma cells after myeloablation, or whether it is in part attributable to contamination of the stem cell harvest with viable malignant cells. Positive selection of CD34 + cells markedly reduces plasma cell contamination. We performed a case controlled analysis in which 15 patients with myeloma who underwent autologous PBSCT with CD34 + cell selection using the Ceprate System (index group), were compared with 15 matched controls. All subjects received an identical preparative regimen. The median times to neutrophils у0.5 × 10 9 /l and unsupported platelets у50 × 10 9 /l were 14 and 23 days for the CD34 + cell selected group and 11 (P = 0.03) and 14 (P = 0.029) for the case controls. Median follow-up of purged patients from autologous PBSCT was 32 months (range 18-43). At 36 months, the probability of PFS was 47 ؎ 14% and 46 ؎ 14% in the index and control groups (P = 0.44). The 3 year probability of OS was 69 ؎ 13% for the CD34 + cell selected arm and 66 ؎ 12.4% in unpurged patients (P = 0.91). Median PFS for the cell selected group is 24 months (CI 19.1-36.0), and 29 months for controls (CI 7.1-50.9). Eleven patients undergoing cell selection remain alive, seven of whom are progression free. At the same time-point after unpurged autologous PBSCT, the corresponding figures are 12 patients alive, with seven remaining progression free. Autologous PBSCT with CD34 + cell selection is both feasible and safe, but results in delayed engraftment as compared to case controls. The 3 year probability of PFS and OS in the cell selected arm was similar to that of the unpurged controls. Our findings indicate that autologous PBSCT with CD34
In multiple myeloma, high-dose chemotherapy in conjunction with autologous stem cell transplantation (ASCT) rescue results in prolonged progression-free (PFS) and overall survival (OS) in comparison to conventional chemotherapy. [1] [2] [3] [4] [5] [6] This is achieved by a substantial reduction in tumour cell burden following myeloablative therapy. There is therefore a rationale that further cytoreduction would produce more durable remissions and consequently prolong survival, and in some patients may even result in complete and sustained eradication of disease.
It is unclear whether relapse is due solely to the presence of residual myeloma cells after myeloablation, or whether it is in part attributable to contamination of the stem cell harvest with viable malignant cells. Methods to increase cytoreduction can therefore be divided into attempts to escalate the dose intensity of the preparative regimen such as by tandem transplantation, 7 or alternatively by in vitro purging of the autologous graft to reduce the re-infusion of potentially neoplastic cells. Support for the latter is provided by the detection, using sensitive PCR-based techniques on marrow and peripheral blood stem cell (PBSC) harvests, of cells with identical IgH rearrangements to the malignant clone. [8] [9] [10] These studies suggest that PBSC are contaminated to a lower order of magnitude than bone marrow grafts. 11 There is evidence from gene-marking studies in patients undergoing autologous PBSCT, that re-infused malignant cells contribute to subsequent relapse in solid tumour patients 12, 13 and in both acute and chronic myeloid leukaemia. 14, 15 A study in myeloma is currently in progress. 16 Immunological purging has the advantage over chemotherapeutic techniques of not exposing the haematopoietic precursors to the effects of chemotherapy. Positive selection of CD34 + cells markedly reduces plasma cell contamination. 10, [17] [18] [19] The Ceprate SC System (CellPro Europe, Paris, France) is a continuous flow immunoadsorption column which positively selects for CD34 antigen expressing cells. The CD34 antigen is a surface marker expressed on early haematopoietic progenitors. 20 It is not present on malignant plasma cells, [21] [22] [23] although its expression on the clonogenic myeloma cell precursor remains controversial. 21 The purification process results in an approximately 2 log
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+ selection of PBSC for transplant in myeloma MK Gandhi et al 370 reduction in myeloma cell contamination within the CD34 enriched fraction. 19, 21 In order to study overall and progression-free survival, we performed a case controlled analysis. Fifteen patients with myeloma who underwent autologous PBSCT with CD34 + cell selection using the Ceprate System, were compared with 15 matched controls. All subjects received an identical preparative regimen 24 and were selected on the basis of their Durie-Salmon prognostic staging score. 25 Patients were well balanced for age, sex, induction treatment, stage at diagnosis, status at transplant, and use of interferon after high-dose therapy.
Patients and methods

Patients
Between May 1994 and November 1996, 17 consecutive patients with multiple myeloma underwent PBSC mobilisation and collection, with the intention of CD34
+ cell selection on the harvested stem cell product. Fifteen of 17 patients went on to receive a purged autologous PBSCT using CD34
+ cell selection (index group). Case controls, all of whom received an identical preparative regimen to the index group, were selected on the basis of their Durie-Salmon prognostic staging score, 25 and were chosen from a pool of 28 patients receiving unselected ASCT for myeloma with BEM conditioning at our institution. Whenever there was more than one potential patient control with the same prognostic score, the patient best matched for age was chosen. Control patients underwent unselected autologous PBSCT between November 1991 and March 1994. Table 1 lists index and control group patient details including age, sex, diagnosis, stage at diagnosis, status at transplant, and use of maintenance alpha interferon after high-dose therapy.
Induction regimens
Two out of 17 consecutive patients chosen for cell selection were excluded from the index group. The first did not mobilise sufficient CD34
+ cells to permit cell selection and had been previously treated with CVAD (cyclophosphamide, vincristine, adriamycin, dexamethasone) induction therapy; the second patient received CD34
+ cell selected cells and supplemental unselected PBSC and bone marrow and had previously been treated with VAD. All 30 (index + control) patients had VAD-based induction chemotherapy. Regimens used were: VAD (13 patients); CVAD (15 patients); VAMP (methylprednisolone substituted for dexamethasone: two patients). One patient control received three cycles of ABCM (adriamycin, BCNU, cyclophosphamide, melphalan) before going on to VAD chemotherapy. No patient received any chemotherapy drug modulating agents. To be eligible for autologous PBSCT, all patients demonstrated a sufficient degree of chemo-sensitivity to their induction regimen, ie CR or PR (see below for definition of disease status). cyclophosphamide. The six patients in the control group transplanted before October 1993 received 7 g/m 2 cyclophosphamide and the nine transplanted after this were given 3 g/m 2 cyclophosphamide. Leucapheresis was performed using a Cobe (Lakewood, CO, USA) continuous flow cell separator as previously described. 5 All CD34 + selected patients received leucapheresis for a minimum of 2 consecutive days. CD34 surface marker analysis was performed using anti-CD34 phycoerthyrin (PE)-conjugated antibody (HPCA2; Becton Dickinson, San Jose, CA, USA) and anti-CD45 FITC-conjugated antibody (Hle-1; Becton Dickinson). Cells were analysed on a Coulter EPICS Elite (High Wycombe, UK) and between 50 000 and 100 000 CD45-positive events were gated for CD34 positivity. Results were expressed as a percentage of the white cell count and converted to a re-infusion dose. A composite CD34 count of 4 × 10 6 /kg body weight was used as the minimum dose considered safe for processing through the Ceprate SC (CellPro, Bothell, WA, USA) system, and after manipulation 2 × 10 6 /kg defined as adequate for proceeding
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+ cell estimation was not routinely performed before March 1994. CFU-GM analysis was performed routinely on patients in both groups after manipulation.
+ cell selection
The leucapheresis product was divided in two and washed manually by centrifugation at 420 g for 10 min in PBS, Ca 2+ and Mg
2+
-free (Chapter, Cambridge, UK) pH 7.2 by at least a 1 in 5 dilution (5 parts PBS:1 part cells). After re-suspension of no more than 60 × 10 9 nucleated cells in PBS containing 0.1% HAS (Zenalb, BPL, Elstree, UK) in a final volume of 150 ml, the cells were incubated for 25 min with 3 ml biotinylated monoclonal anti-CD34 (clone 12.8). The cells were subsequently washed and resuspended in PBS to a final volume of 300 ml (if the nucleated cell count was below 60 × 10 9
). The cells were passed through a 40 m filter to remove any aggregates before loading on to a primed immunoadsorption selection Ceprate SC enclosed column packed with avidin-coated polyacrylamide beads. The biotin-coated cells were allowed to adhere to the surface of the column. Cells not coated with anti-CD34 antibody pass through the system. After gentle agitation, CD34
+ cells were eluted and cryopreserved. Samples of the cell suspension (0.5 ml) were taken during the CD34 selection process to monitor the efficiency of the adsorption and of the whole procedure. Samples were analysed for total nucleated cell count and the percentage of CD34 positivity.
Cryopreservation
The cells were cryopreserved in 10% DMSO (BDH Ltd, Poole, UK) with 4.5% HAS, and placed into Hemofreeze bags (Gambro, Heichingen, Germany) before cryopreservation using a controlled rate freezer (Kryo 10, Biomed, Sutton-on-Thames, UK) and stored in liquid nitrogen.
Preparative regimen
All patients received: intravenous (i.v.) hydration and etoposide 2 g/m 2 on day −3; BCNU 300-450 mg/m 2 as a 2 h infusion on day −2 (with dose adjustment according to lung diffusion capacity); and melphalan 140 mg/m 2 as an i.v. bolus with hydration and forced diuresis on day −1. Stem cells were re-infused a minimum of 24 h following chemotherapy.
Alpha interferon maintenance therapy post autologous PBSCT
Once haematological recovery (WBC count Ͼ2.0 × 10 9 /l and platelets Ͼ100 × 10 9 /l) had been achieved, patients were offered alpha interferon at a dose of 3 mega units subcutaneously three times a week. Interferon was discontinued if poorly tolerated, or once disease progression had occurred.
Definitions of disease status
We applied the EBMT/ IBMTR/ ABMTR response criteria for patients with multiple myeloma undergoing high-dose therapy and stem cell transplantation. 27 To achieve complete remission (CR), four criteria had to be met: (1) no detectable paraprotein in serum or urine by immunoelectrophoresis, maintained for at least 6 weeks; (2) less than 5% plasma cells of normal morphology on bone marrow aspirate; (3) no increase in size or number of lytic lesions; and (4) disappearance of soft tissue plasmacytomas. Patients were regarded as achieving partial remission (PR) if there was a 50% reduction in paraprotein (IgG or IgA myeloma) or bone marrow infiltration (non-secretory myeloma), sustained for a minimum of 6 weeks. For patients in CR, relapse was defined as the reappearance of paraprotein (confirmed by at least one further investigation and excluding oligoclonal reconstitution), or any of bone marrow infiltration у5% or new hypercalcaemia or lytic bone lesions. In patients in PR, progressive disease was defined as a 25% increase in paraprotein on two samples taken at least 6 weeks apart (with an absolute increase of у5 g/l), or development of new lytic bone lesions or hypercalcaemia.
Statistical analysis
Statistical analysis was performed using SPSS for Windows software. Engraftment and survival analysis was of the 15/17 patients (the index group) who went on to receive autologous PBSCT without supplemental unselected bone marrow or PBSC. Median values were compared using the Wilcoxon signed rank test and linear regression used to determine the significance of CFU-GM on engraftment. Engraftment was defined as a sustained neutrophil count у0.5 × 10 9 /l and unsupported platelets у50 × 10 9 /l. Actuarial overall and progression-free survival was evaluated using the Kaplan-Meier product limit method. 28 The difference between curves was tested for statistical significance using the two-tailed log-rank test.
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Results
Progenitor cell yield and CD34
+ cell selection /kg, respectively (P = 0.445).
Transplant-related mortality
Two patients in the index group and one patient receiving unselected cells died of transplant-related complications within 100 days post autologous PBSCT. Deaths were secondary to veno-occlusive disease and adult-respiratory distress syndrome, respectively, in the index group, and due to a massive intra-cerebral haemorrhage in the patient control. Between 100 days and 1 year there were no deaths secondary to transplant-related complications.
Engraftment
All patients, including the three early deaths, successfully engrafted. Sustained neutrophil engraftment (у0.5 × 10 9 /l) was reached at a median of 14 (range 10-21) and 11 (range [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 
days in the CD34
+ selected and control group, respectively (P = 0.03). The median times to unsupported platelets (у50 × 10 9 /l) were 23 (range 13-49) and 14 days (range 9-37) in the index and control groups (P = 0.029). There was a significant linear relationship between CFU-GM values and neutrophil engraftment (P = 0.02), but not with platelet recovery (P = 0.15).
Response
The response to induction treatment as well as response to high-dose therapy is demonstrated in Table 2 . Prior to transplant a total of three patients (two index/one control) had achieved CR (10%). All these remained in continued CR (CCR) at the end of high-dose treatment. Among the patients in PR, a further 10 achieved CR after auto-PBSCT. This resulted in an overall CR rate of 43% (40% index vs 47% control).
Survival
The analysis was carried out in September 1998. Median follow-up time from high-dose therapy in the surviving patients was 32 (range and 57 (range 34-75) months in the index and control groups, respectively. There was one death (in the control arm) within 1 year due to disease relapse. At 36 months from transplant, the probability of PFS was 47 Ϯ 14% and 46 Ϯ 14% in the index and control groups (P = 0.91) (Figure 1) . The 3 year probability of OS was 69 Ϯ 13% for the CD34 + cell selected arm and 66 Ϯ 12.4% in unpurged patients (P = 0.44) (Figure 2 ). Median PFS for the cell selected group is 24 months (CI 19.1-36.0), and 29 months for controls (CI 7.1-50.9) (P = 0.44). Eleven patients who underwent cell selection are alive, seven of whom remain progression free. At the same time-point (ie 32 months) after unpurged ASCT, the corresponding figures are 12 patients alive, with seven remaining progression free.
Discussion
Since the pioneering work of McElwain and Powles in the 1980s, 30 the use of high-dose therapy and autologous stem cell transplantation for multiple myeloma has become widespread. A series of non-randomised studies reported CR rates of 25-75%. 1, 2, 4, 5 The randomised prospective trial conducted by the Intergroupe Français du Myelome 6 demonstrated that autologous BMT resulted in superior out-
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+ selection of PBSC for transplant in myeloma MK Gandhi et al 373 come in comparison to conventional chemotherapy. Their median duration of response was only 27 months despite a CR/very good PR rate of 38%. With longer follow-up, almost all patients receiving high-dose therapy will relapse. 3 Therefore, the therapeutic aim of autologous transplantation remains essentially palliative, ie to prolong time to disease progression, and methods to eradicate disease remain elusive. The absence of a plateau in the curve for PFS justifies the use of new strategies.
The rationale behind autologous PBSCT with CD34 + cell selection is the assumption that disease progression in myeloma is at least in part attributable to contamination of the stem cell harvest with viable malignant cells. The potential advantage of autologous PBSCT with CD34 + cell selection is to improve PFS, and in some cases to achieve sustained remission, by means of reducing the number of myeloma cells re-infused. In order to test this hypothesis, we performed a case controlled analysis. Fifteen patients with myeloma who underwent autologous PBSCT with CD34 + cells isolated using the Ceprate System were compared with 15 controls. All subjects received an identical preparative regimen. 24 Case controls were matched according to the Durie-Salmon prognostic staging index at diagnosis, and were well balanced for age, sex, induction therapy, disease status at transplant, and use of maintenance alpha interferon after high-dose therapy.
Sixteen out of 17 consecutive patients successfully mobilised sufficient cells to permit CD34 + cell selection. This compares favourably with a recent study 18 of CD34 + cell selection, in which 12 of 36 mobilised Ͻ4.0 × 10 6 /l. The authors explain this is as a likely consequence of the high proportion (75%) of the poor mobilisation group receiving prior alkylator therapy. Melphalan has been shown to adversely predict for CD34 + cell yield. 31 None of the 17 patients in our study had received prior melphalan.
All patients receiving cell selected autologous PBSCT achieved sustained engraftment. However, rates of neutrophil and platelet recovery were significantly delayed in comparison to the control group (P = 0.03 and P = 0.029, respectively). We accept that heterogeneity of mobilisation regimens in the control group may have contributed to this observation, although no significant difference was seen between stem cell yields in index and control groups. Gupta et al 18 also observed a significantly longer time for platelets to reach у50 × 10 9 /l in cell selected patients vs controls (P = 0.01), but no difference was seen with neutrophil recovery. However the use of G-CSF for infection or prolonged neutropenia in 60% of CD34 + cell selected patients and 38% of controls may have influenced their findings in this regard. The time needed for platelet reconstitution has also been shown to be prolonged using immuno-magnetic methods of CD34 + cell selection. 19 Delayed reconstitution may be secondary to the reduction in peripheral blood progenitor cells as a consequence of the CD34 + cell selection process. Overall median reduction of CD34 + cells in our study was 45.5% after manipulation which is similar to that published previously, 32, 33 with significant losses attributed to the manual washing method and to retention within the adsorption column (data not shown). Alternatively, earlier recovery in unpurged patients may be initiated by components other than the progenitors included in the CD34 + cell fraction. 34 Although T cell defects exist after ASCT, severe viral infections facilitated by abnormal T cell function are rare. 35 However, CD34
+ selection results in concomitant T cell depletion, and quantitative CD4-positive cell recovery appears to be delayed. 36 Whether this results in a higher rate of severe viral infections, as in T cell depletion in the allogeneic setting is unknown. 37 In lethally irradiated nonhuman primates, purified allogeneic CD34
+ cells devoid of mature T and B lymphocytes have been shown to restore lymphopoiesis. 38 We did not observe severe viral infectious complications in our cohort of patients. A study in which we will compare functional immune reconstitution after CD34
+ cell selected and unpurged autologous PBSCT is currently in progress.
At 36 months from transplant, there was a virtually identical probability of PFS (P = 0.44) and OS (P = 0.91) in the CD34 + cell selection patients as compared to patient controls. The 3-year median PFS achieved in each arm is similar to that reported by the Intergroupe Français du Myelome 6 at a comparative time-point. Our findings indicate that autologous PBSCT with CD34
+ cell selection appears not to have any favourable effect on disease progression. We accept that 6/15 control patients received a higher dose of cyclophosphamide priming (7 g/m 2 ) as compared to the 3 g/m 2 administered to the index group and remaining nine patient controls. This may have resulted in further myeloma cytoreduction, and contributed to improved PFS. However, both the status at diagnosis and post high-dose therapy were comparable between groups. Additionally, three out of the six patients remained in PR post autologous PBSCT and the CR rate after transplant was similar regardless of cyclophosphamide dose, suggesting that the contribution of the two different priming regimens on PFS was minimal. Nonetheless, numbers in this study were small and there is a need for large, well-designed studies to help address the value of purging. A single-arm study of 55 patients with myeloma receiving high-dose therapy and autologous PBSCT using the Ceprate system has been reported. 39 Median follow-up was 33 months. The actuarial probability of PFS was 29 Ϯ 14% which appears similar to reports of unmodified ASCT. Gupta et al 18 reported a non-randomised study, with a median follow-up of 23 months, in which 20 patients receiving CD34
+ cell selected autologous PBSCT were compared with 16 controls. There was no significant difference seen in event-free survival (EFS) between the cell selected group and the unselected controls (median 21 and 26 months, respectively). Tumour cell contamination was evaluated before and after cell selection by IgH gene fingerprinting (fpPCR), and in two patients the clonal cells were quantified by ASO-PCR. Cell selection reduced contamination but did not eliminate it. There was no significant difference in the degree of response or in EFS between those receiving fpPCR-positive or -negative cells. A randomised study is currently in progress which will further determine the role of CD34 + cell selection. Of the six patients in CR after high-dose therapy and CD34 + cell selected autologous PBSCT, only three currently remain in remission. There are a number of possible explanations. Firstly, disease progression may be primarily due to the presence of residual myeloma cells that have not been entirely eradicated by the preparative regimen. The relative chemo-resistance of the plasma cell clone is due to a variety of anti-apoptotic survival mechanisms involving abnormalities of several oncogenes and tumour suppressor genes. 40 The high relapse rate seen after allogeneic BMT for myeloma, 41, 42 suggests that even a stem cell harvest free of tumour cell contamination may not prevent recurrence.
An alternative explanation for the similar survival curves between the two groups is that CD34 + cell selection may have resulted in insufficient purging of myeloma cells. Previous workers 10, 18, 19, 21 have demonstrated using molecular analysis that the cell selection process produces an approximately 2 log reduction in myeloma cell contamination within the CD34 enriched fraction. However, in our study we found that after cell selection the overall median CD34 purity was still only 86% (which is similar to that published previously 18 ) ie there remain 14% of cells with an unknown specificity. The latter fraction may have included potentially malignant plasma cells. Following positive selection, negative purging of the graft with monoclonal antibodies may have resulted in further tumour cell reduction. 43 However, additional manipulation of the graft may lead to further CD34
+ cell loss, and thus a higher starting number would need to be harvested. The low CD34
+ cell recovery reported here may mean that this positive cell selection procedure is only suitable for those patients who produce twice the recommended minimum safe numbers of CD34 + cells for rapid engraftment and that further negative purging may not be possible if it were associated with further CD34 + cell loss.
The CD34 antigen is a surface marker expressed on early haematopoietic progenitors. 20 It is not present on malignant plasma cells. [21] [22] [23] In patients with myeloma, CD34 + CD19 + clonotypic circulating B cells have been identified that express IgH VDJ sequences identical to that of the malignant bone marrow plasma cell. 23 The relationship of circulating CD34
+ clonotypic B cells to the malignant process is as yet undefined, and it is unclear whether re-infusion of clonotypic cells contributes to disease progression.
In conclusion, autologous PBSCT with CD34 + cell selection is both feasible and safe, but results in delayed engraftment as compared to well matched case controls. The 3 year probability of PFS and OS in the cell selected arm was similar to that of the unpurged controls. Our findings indicate that autologous PBSCT with CD34
+ cell selection appears not to have any favourable effect on disease progression. However, the results of this case controlled analysis should be cautiously interpreted, and the role of CD34
+ selection in autologous PBSCT should be further investigated by large randomised trials.
